It is generally believed that exogenously administered A.C.T.H. and corticosteroids suppress the secretion of endogenous A.C.T.H. and possibly also of thyroid-stimulating hormone and growth hormone (Ackerman, Smith, and Miller, 1961; Hartog, Gaafar, and Fraser, 1964; Graber, Ney, Nicholson, Island, and Liddle, 1965) . However, information regarding the effect of these forms of treatment on pituitary gonadotrophic function is conflicting. In the reports of Maddock, Chase, and Nelson (1953) , Lemon (1957) , and Brown, Thorburn, and Crooks (1963) patients with a variety of diseases were studied; in the majority of subjects treatment with A.C.T.H. or corticosteroids caused a rise in the output of human pituitary gonadotrophins. On the other hand, Segaloff, Carabasi, Horwitt, Schlosser, and Murison (1954) observed a decrease in levels of pituitary gonadotrophins in a proportion of women with metastatic mammary carcinoma during treatment with corticosteroids. Sohval and Soffer (1951) , who conducted their assays in patients suffering from disseminated lupus erythematosus and allied conditions, obtained inconsistent results bearing no obvious relationship to the clinical response to treatment.
This problem has been reinvestigated by conducting serial assays of pituitary gonadotrophins in patients with major intestinal conditions, especially ulcerative colitis and Crohn's disease, before, during, and following treatment with A.C.T.H. and synthetic corticosteroid analogues. In all subjects the effects of these forms of treatment on excretion of pituitary gonadotrophins have been correlated with the clinical response. The present communication, a preliminary account of which has been given else-597 where (Crean, Bell, Card, Loraine, and Sircus, 1963) , reports the results obtained.
MATERIALS AND METHODS
COMPOUNDS ADMINISTERED Naturally occurring A.C.T.H. (corticotrophin, Armour) was given by the intramuscular route. Prednisolone (11,17o,21-trihydroxy-pregn-1,4-diene-3,20-dione) and betamethazone (11fl,17ca,21-trihydroxy-9oa-fluoro-16,B-methylpregn-1 ,4-diene-3,20-dione) were administered orally.
PATIENTS Seventeen subjects were investigated. Clinical details, together with treatment and response in terms of excretion of pituitary gonadotrophins, are summarized in Tables I and II. All the patients were in hospital during the initial period of study; in three (1, 5, and 13) assays were conducted on two occasions during separate periods of treatment.
ASSESSMENT OF CLINICAL RESPONSE The investigation of each patient was conducted in the form of a 'doubleblind' trial in which independent assessments were made of the therapeutic effect of A.C.T.H. and corticosteroids on the one hand and of the changes in excretion of pituitary gonadotrophins on the other. The therapeutic response of individual cases was determined as far as possible on objective evidence, but as might have been expected, some form of subjective clinical assessment had also to be made in certain instances. It was considered that the 'double-blind' method of assessing the results effectively eliminated any errors which might have arisen due to observer bias and which might have prejudiced the subjective clinical assessments.
Three categories of clinical response were recognized, namely, good response, partial response, and no response. It must be emphasized that this classification was made only on the basis of the changes observed during the G. P. Crean, J. A. Loraine, E. T. Bell, W. L Card, and W. Sircus period of investigation; the subsequent course of individual patients was not considered in the classification.
HORMONE ASSAY METHODS Estimations of human pituitary gonadotrophins in urine were performed by the method of Loraine and Brown (1959) . The end point of the bioassay was the mouse uterus test, results being expressed in terms of the First International Reference Preparation for Human Menopausal Gonadotrophin (1st I.R.P.-H.M.G.) as H.M.G. units per 24-hour urine sample. The assay method measures 'total gonadotrophic activity' and is not specific for either follicle-stimulating hormone or luteinizing hormone. As employed in this Unit the technique has a high degree of precision, the index of precision (A) (Gaddum, 1933) being generally below 0-20 (SchmidtElmendorff, Loraine, and Bell, 1962) .
In a limited number of patients urinary steroid assays were performed in addition to estimations of gonadotrophins. In such subjects total 17-hydroxycorticosteroids and total 17-oxosteroids were determined by the methods of Appleby, Gibson, Norymberski, and Stubbs (1955) and Vestergaard (1951) .
It will be noted that of 11 patients in whom the clinical response was good (Table I) there was a marked rise in output of gonadotrophins in eight (73 %). On the other hand in four patients in whom a partial response was obtained (Table II ) a marked rise in excretion was noted in only one of the seven treatment periods (14 %). In the three subjects who failed to respond levels of pituitary gonadotrophins remained within the appropriate normal range throughout.
Figures 1 to 9 show examples of the effect of treat- At the time of his first admission to hospital he showed considerable diarrhoea and weight loss, there being radiological evidence of extensive mucosal ulceration in the terminal ileum, caecum, and ascending colon. His symptoms improved markedly following commencement of therapy by A.C.T.H.; this was associated with a marked increase in body weight and restoration to normal of the radiological appearances of the small and large bowel.
Before treatment levels ofpituitary gonadotrophins were within the normal range for a male subject (Fig. 2) . Excretion values increased rapidly following the initiation of therapy, the output almost doubling within 48 hours and reaching a peak of 64 H.M.G. units per 24 hours on days 55 and 56 of the study. Thereafter, gonadotrophin output decreased despite continued administration of the drug and had returned to control values at the time at which treatment was discontinued. During the second course oftherapyexcretion values again increased, reaching a maximum on day 123. Levels decreased subsequently and, at the completion of the investigation, were again within the normal range.
Patient 2 (Fig. 3) This post-menopausal woman was studied during her first major attack of ulcerative colitis. She had been receiving thyroxine for several years for hypothyroidism, and this drug was continued at a dose level of 0 3 mg. per day throughout the greater part of the period of investigation. figure is at the upper end of the normal range for post-menopausal subjects (Apostolakis and Loraine, 1960) . During and following treatment output increased to levels considerably above this range.
Patient 3 (Fig. 4) This patient with an enterocolitis of uncertain cause did not receive hormonal therapy during the period of investigation. He was studied during his first attack, the symptoms of which had been present continuously for six months. At the time of admission to hospital the main clinical features were diarrhoea, marked weight loss, intermittent fever and tachycardia. Sigmoidoscopic and radiological examination revealed an active ulcerative process involving the entire colon. He was treated with a high-caloric, high protein, low-residue diet, in association with vitamin, mineral and electrolyte supplements together with infusions of plasma. With this regime his condition improved markedly and at the time of his discharge from hospital, he had gained approximately 14 kg. in body weight.
The first three assays of pituitary gonadotrophins were within the normal range for a male subject. There were four subjects in this category (Table II) . The results obtained in two of these will be described in detail. Patient 12 (Fig. 6 ) This was the second period of study in a male subject with ulcerative colitis who had previously been treated with prednisolone ( Fig. 8) and had failed to respond. At the commencement of the present investigation he showed fever, moderate anaemia, and diarrhoea; sigmoidoscopic examination revealed widespread changes typical of ulcerative colitis. When treated with A.C.T.H. considerable improvement occurred in his condition, but the colonic mucosa remained abnormal.
Excretion of pituitary gonadotrophins before treatment was within the normal range for a male subject. Variable readings were encountered during therapy but at no time did abnormally high levels occur.
Patient 13 (Fig. 7 (Table II) . Results in two will be described.
Patient 12 (Fig. 8 (Zubiran and Gomez-Mont, 1953; Bell, Harkness, Loraine, and Russell, 1966) . Moreover, Loraine, Douglas, Falconer, and Strong (1961) The effects of gross nutritional changes on the secretion of gonadotrophic hormones in experimental animals also provide some support for the hypothesis adopted. It is now well established that a marked degree of gonadal atrophy may occur as a result of malnutrition in various animal species, including rats and guinea-pigs, despite the fact that the gonadotrophins are present in the pituitary gland in normal or even in increased amounts. It is also known that the gonadal atrophy which accompanies severe malnutrition may be rapidly corrected on the resumption of a normal diet (Meites, 1953; Meites and Reed, 1949; Rinaldini, 1949; Pearse and Rinaldini, 1950 ; see also Leathem, 1961; Chester Jones and Ball, 1962 , for reviews). Various explanations can be suggested for these findings, including storage and subsequent release of gonadotrophic hormones, alterations in their rate of production following refeeding and changes in the hypothalmic control of the anterior pituitary gland.
The precise mechanism responsible for the increase in excretion of pituitary gonadotrophins in patients with intestinal diseases is not at present clear. Presumably, however, one or more of the explanations listed above could account for the results obtained. In the study reported herein pituitary function may have been influenced eitherbyA.C.T.H. or corticosteroid therapy or by the complex changes which may be presumed to accompany recovery from a severe wasting illness. It has not been possible in the present investigation to separate these two factors and to determine the causative mechanism. However, such a separation might be more readily achieved by estimating levels of pituitary gonadotrophins in two other groups of subjects, the first receiving hormonal therapy for diseases such as rheumatoid arthritis and asthma in which nutritional factors are generally of relatively little importance, and the second, patients with a severe debilitating illness, e.g., tuberculosis or malabsorption, who are being treated by methods other than hormone administration. Studies of this type are currently in progress at this Unit and the results obtained will be reported in subsequent papers.
SUMMARY
The effect of A.C.T.H. and corticosteroids on the urinary excretion of human pituitary gonadotrophins has been investigated in 17 patients with intestinal disorders, especially ulcerative colitis and Crohn's disease.
In general, a good clinical response to these forms of treatment is associated with a marked rise in pituitary gonadotrophin output often to levels considerably above the appropriate normal range. On the other hand, in patients showing a partial response or no response, there is little or no effect on gonadotrophin excretion. It is suggested that the rise in output of pituitary gonadotrophins in patients responding well to treatment is due to an improvement in general health.
Assays of pituitary gonadotrophins are not of value in predicting the response of patients with intestinal disorders to treatment with A.C.T.H. or corticosteroids.
In the performance of the assays the skilled assistance of many technicians at the Clinical Endocrinology Research Unit was much appreciated.
